Unity Biotechnology, Inc. (UBX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
285 East Grand Avenue
South San Francisco, CA 94080
United States of America (the)
Phone
650 416 1192
Sector
Healthcare
Industry
Biotechnology
Employees
16
First IPO Date
May 03, 2018
| Name | Title | Pay | Year Born |
| Anirvan Ghosh | Chief Executive Officer & Director | 953,706 | 1965 |
| Nathaniel E. David | Co-Founder & Independent Director | 49,500 | 1968 |
| Alexander Hieu Nguyen | Chief Legal Officer & Head of Operations | 622,968 | 1978 |
| Federico Grossi | Chief Medical Officer | 635,790 | 1974 |
| Lynne Marie Sullivan | Chief Financial Officer & Head of Corporate Development | 679,956 | 1966 |
| Przemyslaw Sapieha | Chief Scientist | 0 | N/A |
| Alicia Tozier | Chief Strategy Officer | 0 | N/A |
| Jan van Deursen | Founder | 0 | N/A |
Unity Biotechnology, Inc. is a biotechnology firm specializing in the development of therapeutic solutions aimed at slowing, halting, or even reversing age-associated diseases. Leading its pipeline, the drug candidate UBX1325 is currently undergoing Phase II clinical trials to treat age-related vision disorders, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. Additionally, the company is advancing UBX1967 for various ophthalmologic conditions, while UBX2050, a human anti-Tie2 agonist monoclonal antibody, also targets age-related eye diseases. Furthermore, UBX2089, an a-Klotho hormone drug candidate, is in development for numerous neurological indications. Established in 2009 as Forge, Inc., the company adopted the name Unity Biotechnology, Inc. in January 2015 and is headquartered in South San Francisco, California.